Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
- Authors:
- Joshua Zhang
- Lily Darman
- Md Sazzad Hassan
- Urs Von Holzen
- Niranjan Awasthi
-
Affiliations: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA - Published online on: October 4, 2023 https://doi.org/10.3892/or.2023.8643
- Article Number: 206
-
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Cox AD and Der CJ: Ras history: The saga continues. Small GTPases. 1:2–27. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bryant KL, Mancias JD, Kimmelman AC and Der CJ: KRAS: Feeding pancreatic cancer proliferation. Trends Biochem Sci. 39:91–100. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hobbs GA, Der CJ and Rossman KL: RAS isoforms and mutations in cancer at a glance. J Cell Sci. 129:1287–1292. 2016.PubMed/NCBI | |
|
Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, Zhang W and Qin JJ: Targeting KRAS mutant cancers: From druggable therapy to drug resistance. Mol Cancer. 21:1592022. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Waters AM and Der CJ: KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 8:a0314352018. View Article : Google Scholar : PubMed/NCBI | |
|
Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS and DePinho RA: Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17:3112–3126. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR, et al: Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature. 524:361–365. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, et al: Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25:717–729. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Buscail L, Bournet B and Cordelier P: Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 17:153–168. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dey P, Kimmelman AC and DePinho RA: Metabolic Codependencies in the tumor microenvironment. Cancer Discov. 11:1067–1081. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Shen X, Niu N and Xue J: Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma. J Transl Int Medicine 0. -. 2022. View Article : Google Scholar | |
|
Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, Laing S, Kruspig B, Upstill-Goddard R, Shaw R, et al: Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10:872–887. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dey P, Li J, Zhang J, Chaurasiya A, Strom A, Wang H, Liao WT, Cavallaro F, Denz P, Bernard V, et al: Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment. Cancer Discov. 10:608–625. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Santana-Codina N, Roeth AA, Zhang Y, Yang A, Mashadova O, Asara JM, Wang X, Bronson RT, Lyssiotis CA, Ying H and Kimmelman AC: Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun. 9:49452018. View Article : Google Scholar : PubMed/NCBI | |
|
Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, et al: Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 496:101–105. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Raho S, Capobianco L, Malivindi R, Vozza A, Piazzolla C, Leonardis FD, Gorgoglione R, Scarcia P, Pezzuto F, Agrimi G, et al: KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth. Nat Metab. 2:1373–1381. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kessler D, Gmachl M, Mantoulidis A, Martin LJ, Zoephel A, Mayer M, Gollner A, Covini D, Fischer S, Gerstberger T, et al: Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci USA. 116:15823–15829. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vigil D, Cherfils J, Rossman KL and Der CJ: Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy? Nat Rev Cancer. 10:842–857. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cuesta C, Arévalo-Alameda C and Castellano E: The importance of being PI3K in the RAS signaling network. Genes (Basel). 12:10942021. View Article : Google Scholar : PubMed/NCBI | |
|
Krygowska AA and Castellano E: PI3K: A crucial piece in the RAS signaling puzzle. Cold Spring Harb Perspect Med. 8:a0314502018. View Article : Google Scholar : PubMed/NCBI | |
|
Hemmings BA and Restuccia DF: PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 4:a0111892012. View Article : Google Scholar : PubMed/NCBI | |
|
Fritsch R and Downward J: SnapShot: Class I PI3K isoform signaling. Cell. 154:940–940.e941. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Y, Wang Y, Zhou C, Mei W and Zeng C: PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol. 12:8191282022. View Article : Google Scholar : PubMed/NCBI | |
|
Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS and Ranieri E: The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: An updated review. Cancers (Basel). 13:39492021. View Article : Google Scholar : PubMed/NCBI | |
|
Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et al: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 6:67442015. View Article : Google Scholar : PubMed/NCBI | |
|
Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, et al: Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell. 29:75–89. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Workman P, Clarke PA, Raynaud FI and van Montfort RL: Drugging the PI3 kinome: From chemical tools to drugs in the clinic. Cancer Res. 70:2146–2157. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ng SS, Tsao MS, Nicklee T and Hedley DW: Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 7:3269–3275. 2001.PubMed/NCBI | |
|
Fujiwara M, Izuishi K, Sano T, Hossain MA, Kimura S, Masaki T and Suzuki Y: Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res. 27:762008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, Maehara SI, Maehara Y and Nakamura K: PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol. 50:606–612. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Luo G and Qiu Z: Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. Oncol Lett. 19:1999–2004. 2020.PubMed/NCBI | |
|
Hu C, Dadon T, Chenna V, Yabuuchi S, Bannerji R, Booher R, Strack P, Azad N, Nelkin BD and Maitra A: Combined inhibition of cyclin-dependent kinases (Dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models. Mol Cancer Ther. 14:1532–1539. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Massihnia D, Avan A, Funel N, Maftouh M, van Krieken A, Granchi C, Raktoe R, Boggi U, Aicher B, Minutolo F, et al: Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. J Hematol Oncol. 10:92017. View Article : Google Scholar : PubMed/NCBI | |
|
Utomo WK, Narayanan V, Biermann K, van Eijck CHJ, Bruno MJ, Peppelenbosch MP and Braat H: mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Lett. 346:309–317. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J and Rozengurt E: Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One. 8:e572892013. View Article : Google Scholar : PubMed/NCBI | |
|
Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB, Lu WF, Lin S, Ma HB, Wang XJ and Wu WY: Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. Drug Des Devel Ther. 7:149–159. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Azzariti A, Porcelli L, Gatti G, Nicolin A and Paradiso A: Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol. 75:1035–1044. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AYM, Scarlett CJ, Chang DK, Pajak MZ, et al: Targeting mTOR dependency in pancreatic cancer. Gut. 63:1481–1489. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN and Hursting SD: Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct MicroRNA-regulated mechanisms. Diabetes. 64:1632–1642. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tuncyurek P, Mayer JM, Klug F, Dillmann S, Henne-Bruns D, Keller F and Stracke S: Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: A novel adjunct to standard chemotherapy? Eur Surg Res. 39:380–387. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Peng T and Dou QP: Everolimus inhibits growth of gemcitabine-resistant pancreatic cancer cells via induction of caspase-dependent apoptosis and G(2) /M arrest. J Cell Biochem. 118:2722–2730. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW and Jusko WJ: Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J. 15:78–84. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wei F, Zhang Y, Geng L, Zhang P, Wang G and Liu Y: mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. Int J Mol Sci. 16:3267–3282. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW and Jusko WJ: Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol. 71:1231–1240. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM and Knudsen ES: Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer. Cell Rep. 16:2017–2031. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA: The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun. 331:295–302. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ito D, Fujimoto K, Mori T, Kami K, Koizumi M, Toyoda E, Kawaguchi Y and Doi R: In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer. 118:2337–2343. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cao P, Maira SM, García-Echeverría C and Hedley DW: Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer. 100:1267–1276. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Awasthi N, Yen PL, Schwarz MA and Schwarz RE: The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem. 113:784–791. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A and Bhalla KN: Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 3:1416–1427. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JE, Woo MG, Jung KH, Shin SM, Son MK, Fang Z, Yan HH, Park JH, Yoon YC, Kim YS and Hong SS: Combination therapy of the active KRAS-targeting antibody inRas37 and a PI3K inhibitor in pancreatic cancer. Biomol Ther (Seoul). 30:274–283. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J and Rozengurt E: Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2. Mol Cancer Ther. 14:1014–1023. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Venkatasubbarao K, Choudary A and Freeman JW: Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res. 65:2861–2871. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M and Nielsen LL: The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. 46:387–393. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R and Zoli W: Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol. 220:214–221. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wei G, Wang M and Carr BI: Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. J Cell Physiol. 224:112–119. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Z, Jung KH, Yan HH, Kim SJ, Rumman M, Park JH, Han B, Lee JE, Kang YW, Lim JH and Hong SS: Melatonin synergizes with sorafenib to suppress pancreatic cancer via melatonin receptor and PDGFR-β/STAT3 pathway. Cell Physiol Biochem. 47:1751–1768. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Awasthi N, Zhang C, Hinz S, Schwarz MA and Schwarz RE: Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res. 32:122013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakkina SP, Gitto SB, Beardsley JM, Pandey V, Rohr MW, Parikh JG, Phanstiel O IV and Altomare DA: DFMO improves survival and increases immune cell infiltration in association with MYC downregulation in the pancreatic tumor microenvironment. Int J Mol Sci. 22:131752021. View Article : Google Scholar : PubMed/NCBI | |
|
Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, Borgman CA, Stelow EB, Lowrey BT, Chopivsky ME, et al: Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia. 15:143–155. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Awasthi N, Monahan S, Stefaniak A, Schwarz MA and Schwarz RE: Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget. 9:5274–5286. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chao MW, Chang LH, Tu HJ, Chang CD, Lai MJ, Chen YY, Liou JP, Teng CM and Pan SL: Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clin Epigenetics. 11:852019. View Article : Google Scholar : PubMed/NCBI | |
|
Amada K, Hijiya N, Ikarimoto S, Yanagihara K, Hanada T, Hidano S, Kurogi S, Tsukamoto Y, Nakada C, Kinoshita K, et al: Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor. Cancer Sci. 114:2189–2202. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Zhao T, Ma L, Liang M, Guo YJ and Zhao LM: Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling. Oncotarget. 8:103167–103181. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, et al: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 25:628–640. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yan Z, Ohuchida K, Fei S, Zheng B, Guan W, Feng H, Kibe S, Ando Y, Koikawa K, Abe T, et al: Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. J Exp Clin Cancer Res. 38:2212019. View Article : Google Scholar : PubMed/NCBI | |
|
Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM, et al: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 83:141–157. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A and Lim KH: Concurrent HER or PI3K inhibition potentiates the antitumor effect of the erk inhibitor ulixertinib in preclinical pancreatic cancer models. Mol Cancer Ther. 17:2144–2155. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A and Sebolt-Leopold J: Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther. 11:1193–1202. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dai X, Zhang J, Arfuso F, Chinnathambi Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood). 240:760–773. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Wang H, Ran L, Zhang Z and Jiang R: The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochem Biophys Res Commun. 476:260–266. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA and Schwarz RE: Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Lett. 459:41–49. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas D and Radhakrishnan P: Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 18:142019. View Article : Google Scholar : PubMed/NCBI | |
|
Krempley BD and Yu KH: Preclinical models of pancreatic ductal adenocarcinoma. Chin Clin Oncol. 6:252017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Y, Yang G, Huang H, Fu Z, Cao Z, Zheng L, You L and Zhang T: Preclinical models of pancreatic ductal adenocarcinoma: Challenges and opportunities in the era of precision medicine. J Exp Clin Cancer Res. 40:82021. View Article : Google Scholar : PubMed/NCBI | |
|
Kim RD, Alberts SR, Peña C, Genvresse I, Ajavon-Hartmann A, Xia C, Kelly A and Grilley-Olson JE: Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer. 118:462–470. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Soares HP, Al-Toubah TE, Kim RD, Kim J, Lewis NK and Mahipal A: Final report: A phase I trial of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer. J Clin Oncol. 36:398. 2018. View Article : Google Scholar | |
|
Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Cutsem EV, Pérez-García J, Stathis A, Britten CD, et al: A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 21:730–738. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
McRee AJ, Sanoff HK, Carlson C, Ivanova A and O'Neil BH: A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest New Drugs. 33:1225–1231. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Borazanci E, Pishvaian MJ, Nemunaitis J, Weekes C, Huang J and Rajakumaraswamy N: A Phase Ib study of single-agent idelalisib followed by idelalisib in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Oncologist. 25:e1604–e1613. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Marsh RW, Lima CM, Levy DE, Mitchell EP, Rowland KM Jr and Benson AB III: A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 30:26–31. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hedley D, Moore MJ, Hirte H, Siu L, Vincent M, Jonker H. Mwang D, Nagai J and Dancey J: A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the princess margaret hospital [PMH] phase II consortium. J Clin Oncol. 23:4166. 2005. View Article : Google Scholar | |
|
Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, et al: Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol. 3:516–522. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, Spreafico A, LoConte N, Anders NM, Miles T, et al: A phase I study of dinaciclib in combination with MK-2206 in patients with advanced pancreatic cancer. Clin Transl Sci. 13:1178–1188. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP and Fuchs CS: Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 27:193–198. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA and Abbruzzese JL: Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BMC Cancer. 10:3682010. View Article : Google Scholar : PubMed/NCBI | |
|
Kordes S, Klümpen HJ, Weterman MJ, Schellens JH, Richel DJ and Wilmink JW: Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 75:1135–1141. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Karavasilis V, Samantas E, Koliou GA, Kalogera-Fountzila A, Pentheroudakis G, Varthalitis I, Linardou H, Rallis G, Skondra M, Papadopoulos G, et al: Gemcitabine combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. A Hellenic cooperative oncology group phase I/II study. Target Oncol. 13:715–724. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Amin M, Gao F, Terrero G, Picus J, Wang-Gillam A, Suresh R, Ma C, Tan B, Baggstrom M, Naughton MJ, et al: Phase I study of docetaxel and temsirolimus in refractory solid tumors. Am J Clin Oncol. 44:443–448. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Weinberg BA, Wang H, Witkiewicz AK, Marshall JL, He AR, Vail P, Knudsen ES and Pishvaian MJ: A phase I study of ribociclib plus everolimus in patients with metastatic pancreatic adenocarcinoma refractory to chemotherapy. J Pancreat Cancer. 6:45–54. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Carr RM, Duma N, McCleary-Wheeler AL, Almada LL, Marks DL, Graham RP, Smyrk TC, Lowe V, Borad MJ, Kim G, et al: Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology. 20:1115–1122. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Park H, Williams K, Trikalinos NA, Larson S, Tan B, Waqar S, Suresh R, Morgensztern D, Van Tine BA, Govindan R, et al: A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. Cancer Chemother Pharmacol. 87:337–347. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kordes S, Richel DJ, Klümpen HJ, Weterman MJ, Stevens AJ and Wilmink JW: A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Invest New Drugs. 31:85–91. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, et al: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 21:1301–1306. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL III, Giguere JK and Abbruzzese JL: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study. Invest New Drugs. 23:485–487. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 22:1430–1438. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K and Willett C: Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Onco Targets Ther. 5:161–170. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O and Moore MJ: Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 12:144–151. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D and Lenz HJ: A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 30:1175–1183. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, et al: BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 23:2799–2805. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, Ferrari D, Barni S, Aitini E, Zagonel V, et al: Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Dig Liver Dis. 46:182–186. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, et al: Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 89:284–291. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, Oh DY, Liu Y, Redhu S, Steplewski K and Le N: A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 50:2072–2081. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Huijberts S, van Geel R, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, et al: Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemother Pharmacol. 85:917–930. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, et al: A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma. Clin Cancer Res. 22:61–68. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G and Zhang H: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 23:e105–e115. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Aung KL, McWhirter E, Welch S, Wang L, Lovell S, Stayner LA, Ali S, Malpage A, Makepeace B, Ramachandran M, et al: A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. J Gastrointest Oncol. 13:3216–3226. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Bodoky G, Timcheva C, Spigel DR, Stella PJL, Ciuleanu TE, Pover G and Tebbutt NC: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 30:1216–1223. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kenney C, Kunst T, Webb S, Christina D Jr, Arrowood C, Steinberg SM, Mettu NB, Kim EJ and Rudloff U: Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma. Invest New Drugs. 39:821–828. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rodon J, Tan DW, Laguna IG, Harb W, Beck JT, Bahary N, Rottey S, Zhu Z, Deng S, Kowalski K, et al: 344 Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): Dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial. J Immunother Cancer. 9:A371. 2021. View Article : Google Scholar | |
|
Surana R, Lee JJ, Smaglo BG, Zhao D, Lee MS, Wolff RA, Overman MJ, Willis J, Der CJ and Pant S: Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial). J Clin Oncol. 40:TPS634. 2022. View Article : Google Scholar | |
|
Grierson PM, Tan B, Pedersen KS, Park H, Suresh R, Amin MA, Trikalinos NA, Knoerzer D, Kreider B, Reddy A, et al: Phase Ib study of ulixertinib plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Oncologist. 28:e115–e123. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Raybould AL, Burgess B, Urban C, Naim R, Lee MS and McRee AJ: A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors. J Clin Oncol. 39:3103. 2021. View Article : Google Scholar | |
|
Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak ARA, Stayner LA, Wu Y, Greenwood R, Singh R, et al: A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest New Drugs. 34:740–749. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, et al: Phase Ib study of combination therapy with MEK inhibitor Binimetinib and Phosphatidylinositol 3-kinase inhibitor Buparlisib in patients with advanced solid tumors with RAS/RAF alterations. Oncologist. 25:e160–e169. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ostrem JM and Shokat KM: Direct small-molecule inhibitors of KRAS: From structural insights to mechanism-based design. Nat Rev Drug Discov. 15:771–785. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, et al: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 575:217–223. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, et al: The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10:54–71. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, et al: Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 384:2371–2381. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, et al: BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers. J Hematol Oncol. 15:232022. View Article : Google Scholar : PubMed/NCBI | |
|
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, et al: Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 388:33–43. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Bekaii-Saab TS, Spira AI, Yaeger R, Buchschacher GL, McRee AJ, Sabari JK, Johnson ML, Barve NA, Hafez N, Velastegui K, et al: KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clin Oncol. 40:519. 2022. View Article : Google Scholar | |
|
Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B and Chen LT: NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 108:78–87. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, et al: Identification of MRTX1133, a Noncovalent, potent, and selective KRAS(G12D) inhibitor. J Med Chem. 65:3123–3133. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, et al: Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 28:2171–2182. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB, et al: Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 13:298–311. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Bannoura SF, Khan HY and Azmi AS: KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? Front Oncol. 12:10139022022. View Article : Google Scholar : PubMed/NCBI | |
|
Huang L, Guo Z, Wang F and Fu L: KRAS mutation: From undruggable to druggable in cancer. Signal Transduct Target Ther. 6:3862021. View Article : Google Scholar : PubMed/NCBI | |
|
Gustafson WC, Wildes D, Rice MA, Lee BJ, Jiang J, Wang Z, Chang S, Flagella M, Mu Y, Dinglasan N, et al: Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor. J Clin Oncol. 40:591. 2022. View Article : Google Scholar | |
|
Frank KJ, Mulero-Sánchez A, Berninger A, Ruiz-Cañas L, Bosma A, Görgülü K, Wu N, Diakopoulos KN, Kaya-Aksoy E, Ruess DA, et al: Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Cell Rep Med. 3:1008152022. View Article : Google Scholar : PubMed/NCBI | |
|
Gort E, Johnson ML, Hwang JJ, Pant S, Dünzinger U, Riemann K, Kitzing T and Janne PA: A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors. J Clin Oncol. 38:TPS3651. 2020. View Article : Google Scholar |
